Quest Diagnostics (DGX) Expected to Announce Quarterly Earnings on Tuesday

Quest Diagnostics (NYSE:DGX) is expected to announce its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect the company to announce earnings of $2.36 per share and revenue of $2.7534 billion for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 8:30 AM ET.

Quest Diagnostics Stock Down 1.2%

Shares of NYSE DGX opened at $184.85 on Tuesday. The company has a current ratio of 1.13, a quick ratio of 1.04 and a debt-to-equity ratio of 0.71. Quest Diagnostics has a 12-month low of $157.20 and a 12-month high of $197.55. The firm’s 50-day moving average price is $181.25 and its 200-day moving average price is $180.84. The stock has a market capitalization of $20.56 billion, a price-to-earnings ratio of 21.70, a P/E/G ratio of 2.37 and a beta of 0.66.

Quest Diagnostics Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, January 28th. Shareholders of record on Tuesday, January 13th were given a dividend of $0.80 per share. The ex-dividend date was Tuesday, January 13th. This represents a $3.20 dividend on an annualized basis and a yield of 1.7%. Quest Diagnostics’s dividend payout ratio is 37.56%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on DGX shares. Wall Street Zen cut Quest Diagnostics from a “buy” rating to a “hold” rating in a report on Sunday, January 25th. Jefferies Financial Group raised their price target on Quest Diagnostics from $200.00 to $215.00 and gave the stock a “buy” rating in a research report on Tuesday, October 21st. Mizuho lifted their price objective on shares of Quest Diagnostics from $190.00 to $210.00 and gave the stock an “outperform” rating in a research note on Friday, October 17th. Evercore ISI boosted their price objective on shares of Quest Diagnostics from $185.00 to $190.00 and gave the company an “in-line” rating in a research report on Wednesday, October 8th. Finally, Truist Financial raised their target price on shares of Quest Diagnostics from $195.00 to $205.00 and gave the stock a “hold” rating in a report on Wednesday, October 22nd. Eight equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $198.27.

Insider Transactions at Quest Diagnostics

In related news, SVP Mark E. Delaney sold 7,946 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $187.35, for a total value of $1,488,683.10. Following the transaction, the senior vice president owned 7,530 shares of the company’s stock, valued at $1,410,745.50. This trade represents a 51.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Vicky B. Gregg sold 1,250 shares of the business’s stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $191.76, for a total transaction of $239,700.00. Following the completion of the sale, the director directly owned 17,037 shares of the company’s stock, valued at approximately $3,267,015.12. This trade represents a 6.84% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 64,289 shares of company stock worth $12,318,360. 8.16% of the stock is currently owned by insiders.

Institutional Trading of Quest Diagnostics

Several institutional investors and hedge funds have recently made changes to their positions in the company. State Street Corp grew its holdings in Quest Diagnostics by 0.8% during the 3rd quarter. State Street Corp now owns 5,223,930 shares of the medical research company’s stock worth $995,577,000 after acquiring an additional 38,931 shares in the last quarter. Boston Partners lifted its position in shares of Quest Diagnostics by 32.8% in the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock worth $767,978,000 after purchasing an additional 997,033 shares during the period. Invesco Ltd. boosted its stake in shares of Quest Diagnostics by 1.8% during the third quarter. Invesco Ltd. now owns 1,688,769 shares of the medical research company’s stock valued at $321,846,000 after purchasing an additional 30,418 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Quest Diagnostics by 2.2% during the third quarter. Bank of America Corp DE now owns 1,635,075 shares of the medical research company’s stock valued at $311,613,000 after purchasing an additional 35,473 shares in the last quarter. Finally, Alliancebernstein L.P. boosted its stake in shares of Quest Diagnostics by 5.5% during the second quarter. Alliancebernstein L.P. now owns 1,241,855 shares of the medical research company’s stock valued at $223,074,000 after purchasing an additional 64,283 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.

Quest Diagnostics Company Profile

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.